A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer Metastatic
Interventions: DRUG: Paclitaxel|BIOLOGICAL: Pelareorep|DRUG: Avelumab
Sponsor: Oncolytics Biotech
Collaborators: PrECOG, LLC.